Clinical Trials Logo
  1. Home
  2. Ascites
  3. NCT01349335

Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

Ascites Clinical Trial

Official title:
A Phase 2 Randomized, Double-blinded, Multicenter and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Different Doses of Tolvaptan Tablet in Patients With Cirrhotic Ascites

Clinical Trial Summary

To observe the safety/efficacy of tolvaptan for treatment of patients with hepatic cirrhosis with ascites and exploring the dosage-effect relations of the drug.

Clinical Trial Description

Tolvaptan is able to exert hydragogue diuretic effects (water diuresis) via inhibition of water reabsorption by renal collecting ducts without corresponding increase in electrolyte excretion. It has been confirmed that tolvaptan is able to increase urine volume without any adverse effects on renal functions. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01349335
Study type Interventional
Source Otsuka Beijing Research Institute
Contact
Status Completed
Phase Phase 2
Start date April 2009
Completion date April 2010
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02891642 - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Recruiting NCT00239096 - Prevention of Decompensation in Liver Cirrhosis Phase 4
Active, not recruiting NCT03973866 - Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study) N/A
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Terminated NCT01455246 - Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Completed NCT01578226 - Procalcitonin in Cirrhotic Patients at High Risk for Sepsis N/A
Terminated NCT00548366 - Sodium Restriction in the Management of Cirrhotic Ascites Phase 4
Recruiting NCT05025878 - 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Completed NCT03327688 - Point-of-care Ultrasound in Finland N/A
Not yet recruiting NCT04550091 - Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
Completed NCT01769040 - Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis Phase 4
Not yet recruiting NCT01716611 - Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Phase 4
Recruiting NCT05511766 - Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Phase 2/Phase 3
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Completed NCT05013502 - Empagliflozin in Diuretic Refractory Ascites Phase 1
Not yet recruiting NCT06436807 - PMCF Study of the CE-marked Drainova® ArgentiC Catheter
Completed NCT03263598 - Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
Completed NCT00907673 - The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure N/A
Suspended NCT00511394 - Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis N/A
Terminated NCT00796861 - Trial of Sunitinib for Refractory Malignant Ascites Phase 2